Dr Lal Pathlabs Ltd's Q3FY25 Quarter Results
- 31 Jan 2025
Result Summary
- Dr Lal Pathlabs Ltd reported a 8.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.6%.
- Its expenses for the quarter were down by 3.1% QoQ and up 9.6% YoY.
- The net profit decreased 25.0% QoQ and increased 19.3% YoY.
- The earnings per share (EPS) of Dr Lal Pathlabs Ltd stood at 11.6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 621.80 | 682.10 | 557.20 | -8.8% | 11.6% |
Total Expenses | 483.50 | 499.00 | 441.30 | -3.1% | 9.6% |
Profit Before Tax | 138.30 | 183.10 | 115.90 | -24.5% | 19.3% |
Tax | 40.20 | 52.30 | 33.70 | -23.1% | 19.3% |
Profit After Tax | 98.10 | 130.80 | 82.20 | -25.0% | 19.3% |
Earnings Per Share | 11.60 | 15.50 | 9.80 | -25.2% | 18.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Dr Lal Pathlabs Ltd is a prominent diagnostic and related healthcare service provider in India. The company is well-known for offering a comprehensive range of diagnostic services, which include pathology and radiology testing. As a leading player in the healthcare industry, Dr Lal Pathlabs has established a vast network of laboratories and patient service centers across the country. This widespread network allows it to cater to a diverse customer base, providing high-quality diagnostic services. While specific recent developments in the company are not available in the provided data, Dr Lal Pathlabs typically focuses on expanding its service network and enhancing its diagnostic capabilities to meet the growing demand for healthcare services in India.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Dr Lal Pathlabs Ltd reported a total income of ₹621.80 crores. This figure represents a decline of 8.8% from the previous quarter (Q2FY25), where the company recorded a total income of ₹682.10 crores. However, when compared to the same quarter in the previous fiscal year (Q3FY24), the total income increased by 11.6%, from ₹557.20 crores. These changes in revenue reflect the company's fluctuating performance over the quarters, with a notable year-over-year growth.
Profitability
The company's profitability metrics indicate a decrease in the third quarter of fiscal year 2025 compared to the previous quarter. The profit before tax (PBT) for Q3FY25 was ₹138.30 crores, which is a 24.5% decrease from ₹183.10 crores recorded in Q2FY25. Nonetheless, there was a year-over-year increase of 19.3% from the ₹115.90 crores reported in Q3FY24. The profit after tax (PAT) followed a similar trend, decreasing by 25.0% from ₹130.80 crores in Q2FY25 to ₹98.10 crores in Q3FY25, while exhibiting a 19.3% increase from ₹82.20 crores in Q3FY24. The earnings per share (EPS) also declined by 25.2% quarter-over-quarter, dropping from ₹15.50 to ₹11.60, but rose by 18.4% year-over-year from ₹9.80.
Operating Metrics
Dr Lal Pathlabs Ltd's operating expenses for the third quarter of fiscal year 2025 amounted to ₹483.50 crores, a 3.1% reduction from ₹499.00 crores in the previous quarter. On a year-over-year basis, the operating expenses increased by 9.6% from ₹441.30 crores in Q3FY24. The tax expense for the quarter was ₹40.20 crores, down 23.1% from ₹52.30 crores in Q2FY25, yet up 19.3% from ₹33.70 crores in Q3FY24. These operating metrics reveal significant quarter-over-quarter reductions in both expenses and tax liabilities, while showing a year-over-year increase, reflecting the company's operational adjustments over time.
